Hopp til hovedinnhold
Toggle navigation
Live markets
Search
Search
Search
Search
My profile
My Subscriptions
Watchlists
Quote alerts
Create account
Sign in
NB
FR
EN
PT
NL
NB
DE
IT
Hjem
Company Press Releases
Company press releases
Abonner
Filtre
Filtre
Oppdater
Nullstill
Icon After
Dato
Toggle Visibility
Alle
I dag
Denne uken
Denne måneden
Tilpasset datosøk
Fra
Til
Kategori
Toggle Visibility
Alliances and agreements
Annen informasjonspliktig regulatorisk informasjon
Change in Capital
Commercial operations
Commercial results
Corporate life
Dividend
Eks.dato
Endringer i rettighetene til aksjer / verdipapirer
Flagging
General meeting / Board Meeting
Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll
Ikke-informasjonspliktige pressemeldinger
Income
Innsideinformasjon
Joint venture
Journal / appointments
Kapital- og stemmerettsendringer
Legal
Meetings / events
Meldepliktig handel for primærinnsidere
Mergers, Acquiqitions, Transferts
New
New establishment
News contracts
Other financial transaction
Other subject
Polls / Surveys
Products and services
Prospekt / opptaksdokument
Rapportering om betaling til myndigheter (land-for-land rapportering)
Rating
Renteregulering
Sales
Share history
Share introduction and issues
Takeover bids
Trends / Analyses
Utsteders meldeplikt ved handel i egne aksjer
Valg av hjemstat
Årsrapporter og revisjonsberetninger
Leverandør
Toggle Visibility
ActusNewsWire
BusinessWire
EQS Group
Euronext
GlobeNewswire
Les Echos
Marketwire
Modular Finance
Oslo Børs Newspoint
PR Newswire
Viser 1 - 50 av 112 resultater
Tid
Selskap
Tittel
Sektor
Kategori
28 Jun 2024
08:00 CEST
TME PHARMA
TME Pharma Provides Results of Second Exercise of Warrants Z
20103010 Biotechnology
Other subject
28 Jun 2024
08:00 CEST
TME PHARMA
TME PHARMA PRESENTE LES RÉSULTATS DE LA DEUXIÈME PÉRIODE D’EXERCICE DES BONS DE SOUSCRIPTION Z
20103010 Biotechnology
Other subject
27 Jun 2024
18:00 CEST
TME PHARMA
TME PHARMA ANNONCE LA NOMINATION DE LEE SCHALOP AU CONSEIL DE SURVEILLANCE ET L’APPROBATION DE L’ENSEMBLE DES RÉSOLUTIONS DE L’ASSEMBLÉE GÉNÉRALE ANNUELLE DES ACTIONNAIRES 2024
20103010 Biotechnology
General meeting / Board Meeting
27 Jun 2024
18:00 CEST
TME PHARMA
TME Pharma Announces Appointment of Lee Schalop to Supervisory Board and Approval of All Resolutions Submitted to the 2024 Annual General Meeting of Shareholders
20103010 Biotechnology
General meeting / Board Meeting
18 Jun 2024
08:00 CEST
TME PHARMA
TME PHARMA ANNONCE LE SUCCES DE SON AUGMENTATION DE CAPITAL POUR UN MONTANT DE 2,35 MILLIONS D'EUROS
20103010 Biotechnology
Share introduction and issues
18 Jun 2024
08:00 CEST
TME PHARMA
TME Pharma Announces Results of Successful Capital Increase With €2.35 Million Raised
20103010 Biotechnology
Share introduction and issues
17 Jun 2024
18:40 CEST
TME PHARMA
TME PHARMA ANNONCE UN ACCORD DE GARANTIE DE FINANCEMENT DANS LE CADRE DU LANCEMENT D'UNE AUGMENTATION DE CAPITAL DE MINIMUM 2,2 MILLIONS D'EUROS DESTINEE AUX INVESTISSEURS PROFESSIONNELS ET AUX PARTICULIERS EN FRANCE VIA PRIMARYBID
20103010 Biotechnology
Other subject
17 Jun 2024
18:40 CEST
TME PHARMA
TME Pharma Announces a Financing Guarantee Agreement and the Launch of Capital Increase of Minimum 2.2 Million Euros
20103010 Biotechnology
Other subject
17 Jun 2024
17:35 CEST
TME PHARMA
TME PHARMA ANNONCE LA PUBLICATION DANS NATURE COMMUNICATIONS DES DONNÉES SUR LES BIOMARQUEURS ISSUES DE L'ESSAI DE PHASE 1/2 GLORIA, EVALUANT LE NOX-A12 DANS LE GLIOBLASTOME
20103010 Biotechnology
Other subject
17 Jun 2024
17:35 CEST
TME PHARMA
TME Pharma Announces Publication in Nature Communications of Biomarker Data From NOX-A12 Gloria Phase 1/2 Trial in Glioblastoma
20103010 Biotechnology
Other subject
27 May 2024
08:00 CEST
TME PHARMA
TME Pharma Announces Convocation of the 2024 Annual General Meeting of Shareholders
20103010 Biotechnology
Other subject
27 May 2024
08:00 CEST
TME PHARMA
TME PHARMA ANNONCE LA CONVOCATION DE L’ASSEMBLÉE GÉNÉRALE ANNUELLE DES ACTIONNAIRES 2024
20103010 Biotechnology
Other subject
25 Apr 2024
18:00 CEST
TME PHARMA
TME Pharma Publishes 2023 Financial Results and Provides Operating Update
20103010 Biotechnology
Income
25 Apr 2024
18:00 CEST
TME PHARMA
TME PHARMA PUBLIE SES RÉSULTATS FINANCIERS 2023 ET FAIT LE POINT SUR SES NOMBREUSES AVANCÉES OPÉRATIONNELLES
20103010 Biotechnology
Income
23 Apr 2024
08:00 CEST
TME PHARMA
TME PHARMA ANNONCE QUE 33% DES PATIENTS AYANT REÇU LE NOX-A12 EN COMBINAISON AVEC LE BEVACIZUMAB ET LA RADIOTHÉRAPIE ONT ATTEINT DEUX ANS DE SURVIE DANS L'ESSAI DE PHASE 1/2 GLORIA DANS LE CANCER DU CERVEAU
20103010 Biotechnology
Other subject
23 Apr 2024
08:00 CEST
TME PHARMA
TME Pharma Announces 33% of Patients Receiving NOX-A12 in Combination With Bevacizumab and Radiotherapy Achieve Two‑Year Survival in GLORIA Phase 1/2 Trial in Brain Cancer
20103010 Biotechnology
Other subject
02 Apr 2024
20:45 CEST
TME PHARMA
LA FDA AMERICAINE ACCORDE LA DESIGNATION FAST TRACK POUR NOX-A12, LE PROGRAMME PRINCIPAL DE TME PHARMA, DANS LE CANCER DU CERVEAU
20103010 Biotechnology
Other subject
02 Apr 2024
20:45 CEST
TME PHARMA
TME Pharma Receives US FDA Fast Track Designation for Lead Asset NOX-A12 in Brain Cancer
20103010 Biotechnology
Other subject
28 Mar 2024
08:00 CET
TME PHARMA
TME Pharma Provides Results of First Exercise of Warrants Z
20103010 Biotechnology
Share history
28 Mar 2024
08:00 CET
TME PHARMA
TME PHARMA COMMUNIQUE LES RESULTATS DE LA PREMIERE PERIODE D’EXERCICE DES BONS DE SOUSCRIPTION Z
20103010 Biotechnology
Share history
05 Mar 2024
08:00 CET
TME PHARMA
TME PHARMA ANNONCE L'APPROBATION PAR LA FDA DE LA DEMANDE DE LANCEMENT D’ESSAI CLINIQUE (IND) POUR UN ESSAI DE PHASE 2 EVALUANT NOX-A12 DANS LE CANCER DU CERVEAU
20103010 Biotechnology
New
05 Mar 2024
08:00 CET
TME PHARMA
TME Pharma Announces FDA Clearance of Investigational New Drug (IND) Application for NOX-A12 Phase 2 Trial in Brain Cancer
20103010 Biotechnology
New
23 Feb 2024
08:00 CET
TME PHARMA
TME PHARMA COMMUNIQUE LES RESULTATS DE L'EXERCICE FINAL DES BONS DE SOUSCRIPTION D'ACTIONS Y : 854K€ SUPPLEMENTAIRES LEVÉS, PROLONGEANT SA VISIBILITE DE TRESORERIE DE MAI A JUILLET 2024
20103010 Biotechnology
Other subject
23 Feb 2024
08:00 CET
TME PHARMA
TME Pharma Provides Results of Final Exercise of Warrants Y: Additional €854K Raised and Extension of Cash Runway From May Into July 2024
20103010 Biotechnology
Other subject
09 Feb 2024
08:00 CET
TME PHARMA
TME PHARMA ANNONCE LA FIN DU PROGRAMME D'OBLIGATIONS CONVERTIBLES À LA SUITE DU SUCCÈS D'UN FINANCEMENT DE 1,48 MILLION D'EUROS DESTINÉ AU RACHAT DE L'ENSEMBLE DE LA DETTE CONVERTIBLE ENCORE EN CIRCULATION
20103010 Biotechnology
Other subject
09 Feb 2024
08:00 CET
TME PHARMA
TME Pharma Announces the End of the Convertible Debt Program With the Successful €1.48 Million Financing Intended for Buyback of All Outstanding Convertible Debt
20103010 Biotechnology
Other subject
02 Feb 2024
08:00 CET
TME PHARMA
TME PHARMA ANNONCE DES DONNÉES FINALES DE SURVIE MÉDIANE GLOBALE ATTEIGNANT 19,9 MOIS POUR LE RÉGIME COMBINÉ NOX-A12 DANS L'ESSAI GLORIA SUR LE CANCER DU CERVEAU ET UN TAUX DE SURVIE DIX FOIS PLUS ÉLEVÉ QUE LE TRAITEMENT STANDARD
20103010 Biotechnology
Other subject
02 Feb 2024
08:00 CET
TME PHARMA
TME Pharma Announces Final Median Overall Survival Data Reaching 19.9 Months for NOX-A12 Combination Regimen in GLORIA Brain Cancer Trial and Survival Rate 10-Fold Greater Than Standard of Care
20103010 Biotechnology
Other subject
31 Jan 2024
18:00 CET
TME PHARMA
TME Pharma N.V.: Half-yearly Report on the Liquidity Contract With Invest Securities
20103010 Biotechnology
Share history
31 Jan 2024
18:00 CET
TME PHARMA
TME PHARMA N.V. : BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITÉ CONTRACTÉ AVEC INVEST SECURITIES
20103010 Biotechnology
Share history
23 Jan 2024
18:17 CET
TME PHARMA
TME Pharma Provides Update on Number of Outstanding Shares and Warrants Following First Warrant Y Exercise Period
20103010 Biotechnology
Share history
23 Jan 2024
18:17 CET
TME PHARMA
TME PHARMA FOURNIT UNE MISE À JOUR DU NOMBRE D'ACTIONS ET DE BONS DE SOUSCRIPTIONS EN CIRCULATION SUITE À LA PREMIÈRE PÉRIODE D'EXERCICE DES BONS DE SOUSCRIPTION Y
20103010 Biotechnology
Share history
09 Jan 2024
18:00 CET
TME PHARMA
TME PHARMA ANNONCE LE SUCCES DE LA REUNION DE CONSEIL AVEC LA FDA AMERICAINE SUR LE DÉVELOPPEMENT DU NOX-A12 DANS LE CANCER DU CERVEAU
20103010 Biotechnology
New
09 Jan 2024
18:00 CET
TME PHARMA
TME Pharma Announces Successful Advice Meeting With US Food and Drug Administration on NOX-A12 Development in Brain Cancer
20103010 Biotechnology
New
20 Dec 2023
08:00 CET
TME PHARMA
TME Pharma Announces Further Improvement in Median Overall Survival at 19 Months Follow-up in GLORIA Brain Cancer Trial
20103010 Biotechnology
New
20 Dec 2023
08:00 CET
TME PHARMA
TME PHARMA ANNONCE UNE NOUVELLE AMELIORATION DE LA SURVIE GLOBALE MEDIANE A 19 MOIS DANS L'ESSAI GLORIA SUR LE CANCER DU CERVEAU
20103010 Biotechnology
New
14 Dec 2023
08:00 CET
TME PHARMA
TME Pharma Announces Results of Successful Capital Increase With Preferential Subscription Rights for €2.7 Million
20103010 Biotechnology
Other subject
14 Dec 2023
08:00 CET
TME PHARMA
TME PHARMA ANNONCE LE VIF SUCCÈS DE SON AUGMENTATION DE CAPITAL AVEC DROITS PRÉFÉRENTIELS DE SOUSCRIPTION POUR UN MONTANT DE 2,7 MILLIONS D'EUROS
20103010 Biotechnology
Other subject
28 Nov 2023
08:00 CET
TME PHARMA
TME PHARMA ANNONCE L'OUVERTURE DE LA COTATION DES DROITS PRÉFÉRENTIELS DE SOUSCRIPTION POUR L'AUGMENTATION DE CAPITAL ENTIÈREMENT GARANTIE DE 2,7 MILLIONS D'EUROS
20103010 Biotechnology
New
28 Nov 2023
08:00 CET
TME PHARMA
TME Pharma Announces the Initiation of the Listing of Preferential Subscription Rights for Fully Guaranteed €2.7 Million Capital Increase
20103010 Biotechnology
New
24 Nov 2023
18:06 CET
TME PHARMA
TME Pharma Launches Fully Guaranteed €2.7 Million Preferential Rights Issue With Warrants Attached Combined With Buyback of Convertible Debt
20103010 Biotechnology
Share introduction and issues
24 Nov 2023
18:06 CET
TME PHARMA
TME PHARMA LANCE UNE AUGMENTATION DE CAPITAL ENTIEREMENT GARANTIE DE 2,7 M€ AVEC DROITS PREFERENTIELS DE SOUSCRIPTION (DPS) D’ACTIONS ASSORTIES DE BONS DE SOUCRIPTION (ABSA) ET ANNONCE LE RACHAT D’UNE PARTIE DE SA DETTE CONVERTIBLE
20103010 Biotechnology
Share introduction and issues
18 Nov 2023
08:00 CET
TME PHARMA
TME PHARMA ANNONCE LA PRESENTATION DE DONNEES ADDITIONELLES SUR LE TRAITEMENT EN COMBINAISON DE NOX-A12 DANS LE CANCER DU CERVEAU A L’OCCASION DE LA REUNION ANNUELLE SNO 2023
20103010 Biotechnology
New
18 Nov 2023
08:00 CET
TME PHARMA
TME Pharma Announces Additional Data From NOX-A12 Combination Regimen in Brain Cancer Presented at SNO 2023 Annual Meeting
20103010 Biotechnology
New
27 Oct 2023
18:00 CEST
TME PHARMA
TME Pharma Reports H1 2023 Financial Results and Provides Business Update
20103010 Biotechnology
Other subject
27 Oct 2023
18:00 CEST
TME PHARMA
TME PHARMA PUBLIE SES RÉSULTATS FINANCIERS POUR LE PREMIER SEMESTRE 2023 ET FAIT LE POINT SUR SON ACTIVITÉ
20103010 Biotechnology
Other subject
20 Oct 2023
08:00 CEST
TME PHARMA
TME Pharma Announces Further Improvement in Overall Survival at 18 Months to 67% for NOX-A12 Combination Regimen in Brain Cancer
20103010 Biotechnology
Other subject
20 Oct 2023
08:00 CEST
TME PHARMA
TME PHARMA ANNONCE UNE NOUVELLE AMÉLIORATION DE LA SURVIE GLOBALE À 18 MOIS, PORTÉE À 67% POUR LE TRAITEMENT PAR NOX-A12 EN COMBINAISON DANS LE CANCER DU CERVEAU
20103010 Biotechnology
Other subject
17 Oct 2023
19:00 CEST
TME PHARMA
TME Pharma Reports on End of Six-month Lock-up Period of Shares and Convertible Bonds Following the April 2023 Transaction
20103010 Biotechnology
Other subject
17 Oct 2023
19:00 CEST
TME PHARMA
TME PHARMA ANNONCE LA FIN DE LA PERIODE DE LOCK-UP DE SIX MOIS DES ACTIONS ET DES OBLIGATIONS CONVERTIBLES À LA SUITE DE LA TRANSACTION FINANCIÈRE D'AVRIL 2023
20103010 Biotechnology
Other subject
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Sider
1
2
3
›
››
»
Last »
Company press releases subscription
×
To subscribe to Press releases from this issuer, visit the Subscription to Company news section in
Hjem
Markeder
Amsterdam
Cash Products
Aksjer
AEX index Stocks
AEX ESG Stocks
Indekser
Fond
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksopsjoner
Indeksfutures
Aksjeopsjoner
Utbyttederivater
Aksjefutures
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Brussel
Cash products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
Expert Market
BEL 20 Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Expert Market
Dublin
Stocks
Euronext regulated
Euronext Growth
ISEQ 20 Stocks
Indices
Funds
Bonds
Irish Government Bonds
DOL
Lisboa
Cash Products
Aksjer
Euronext regulated
Euronext Access
PSI Stocks
Indekser
Obligasjoner
Derivater
Indeksfutures
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Milan
Cash Products
Stocks
Euronext Milan
Euronext Growth Milan
Euronext Star Milan
Euronext Global Equity Market
EuroTLX
Trading After Hours
MIB ESG Stocks
Bonds
MOT
Euronext Access Milan
EuroTLX
Structured Products
SeDeX
EuroTLX
ETFs
Funds
Derivative products
All derivatives
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
IPOs
Oslo
Aksjer, renter, indekser
Aksjer
Oslo Børs
Euronext Growth
Euronext Expand
Top performers
OBX aksjer
OBX ESG aksjer
OSEBX aksjer
OSEFX Aksjer
Seafood Aksjer
Shipping Aksjer
Aksjeindekser
Obligasjoner
Oslo Børs
Nordic Alternative Bond Market
Obligasjonsindekser
ETFer
Fond
Derivater
Derivative products
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Finanskalender
Primærinnsidere
Paris
Cash Products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
CAC 40 Stocks
CAC 40 ESG Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Aksjer
All Markets directories
All Markets
Euronext regulated
Euronext Growth
Euronext Access
Euronext Expand
Euronext Global Equity Market
EuroTLX
Trading After Hours
Selskapsmeldinger
Latest
Archive
Nye aksjenoteringer
Alle aksjenoteringer
Euronext Growth advisors
Euronext Tech Leaders
Family business
Indekser
Directory
Grønne indekser
Indices documents
Indices news
Indekser høringer
Kontakter Euronext-indekser
ETF-er
Directory
Grønne ETF-er
Fond
Directory
ESG Funds
Oslo Mutual Funds
Obligasjoner
Grønne obligasjoner
1.5° Bonds
All Markets directories
All Markets
Amsterdam
Brussels
Dublin
Lisbon
Oslo
Milan
Paris
Strukturerte produkter
Directory / search
Bid-Only trading status
Trading Turbos in the Netherlands
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
ETF opsjoner
Kontraktsspesifikasjoner
Tick sizes
Rapportering av handler
Leverandørkoder markedsdata
Råvarer
Quotes
Quotes snapshot
Milling Wheat futures
Rapeseed futures
Corn futures
European Durum Wheat Futures
Milling Wheat options
Rapeseed options
Corn options
Bortfallskalendre
Bortfall
Wholesale Trading
Commitments of Traders (CoT) report
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Knowledge Centre
Bid & Ask
Options Investing E-learning
Contract Specifications
Position Management
Intrinsic Value
Premium & Valuation
Moneyness
Positions
Euronext News
Ressurser
Statistikk & rapporter
Quality of execution
Åpningstider
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Key Information Document
Class level
Product group level
Notices / Corporate actions
Cash Notices / Corporate actions
Derivatives corporate actions
All Corporate Actions
Latest
Unusual Contract Sizes, Dividends
Corporate Action Services
Corporate Action Policies
Derivatives notices
Markedshendelser
Suspenderte instrumenter
Stressed Market Conditions
Brudd på Double Cap limits
Ekstraordinære markedsforhold
Diverse meldinger
Market status
Medlemsliste
Issuers compliance
Hvor du finner hva